{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:28:18Z","timestamp":1780489698986,"version":"3.54.1"},"reference-count":209,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Antibody (Ab)-based therapeutics have become powerful tools across diverse disease areas, with advances in bioengineering giving rise to next\u2212generation molecules designed to outperform conventional Abs. Yet, large-scale production and purification of such complex proteins remain costly and can restrict patient access. A promising alternative is to improve\n                    <jats:italic>in vivo<\/jats:italic>\n                    expression capabilities, which will reduce manufacturing burdens and improve safety and tolerability. Multiple gene delivery platforms - ranging from mRNA and viral vectors to engineered cell therapies - have matured considerably, as a direct result of years of clinical experience and growing regulatory confidence. The rapid deployment of mRNA vaccines against SARS-CoV-2, the clinical success of adeno-associated virus (AAV)- and lentiviral-based interventions, and the approval of chimeric antigen receptor (CAR)-T cell therapies highlight the potential of these technologies to transform how we deliver Ab therapeutics. While these approaches hold the promise to treat genetic aberrations in patients, they may also contribute considerably to advancing conventional Ab therapeutics against viral infections and other diseases through local persistence of the proteins. Looking forward,\n                    <jats:italic>in situ<\/jats:italic>\n                    expression may confer even more benefits for engineered Ab-like molecules, thereby compensating for possibly shorter half-lives and overcoming challenges in\n                    <jats:italic>in vitro<\/jats:italic>\n                    production and purification. Therefore, in this review, we critically evaluate how these established and emerging gene therapy platforms can be harnessed to expand access, and discuss possibilities to improve\n                    <jats:italic>in situ<\/jats:italic>\n                    availability through the choice of transient or stable expression systems to increase the efficacy of Abs and other therapeutic proteins. Furthermore, we explore the current landscape of technological advancements, identify key translational challenges, and project future directions for optimizing these approaches towards widely applicable clinical interventions.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1714390","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:53:06Z","timestamp":1767768786000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic antibody delivery: vector tools to boost efficacy and affordability"],"prefix":"10.3389","volume":"16","author":[{"given":"Abhishek","family":"Chiyyeadu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Ehrhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard","family":"B\u00fcning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schambach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/0734-9750(93)90001-4","article-title":"Monoclonal antibodies in organ transplantation","volume":"11","author":"Powelson","year":"1993","journal-title":"Biotechnol Adv"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363240-00009","article-title":"Basiliximab: A review of its use as induction therapy in renal transplantation","volume":"63","author":"Chapman","year":"2003","journal-title":"Drugs"},{"key":"B3","volume-title":"Antibody therapeutics approved or in regulatory review in the EU or US","year":""},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"key":"B6","first-page":"199","article-title":"Adalimumab","volume-title":"Moderate to Sev Psoriasis Fourth Ed","author":"Debbaneh","year":"2023"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01483-4","article-title":"Ansuvimab: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"B8","first-page":"17","article-title":"Pharmaceutical approval update","volume":"42","author":"Choy","year":"2017","journal-title":"Pharm Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/d41573-023-00130-9","article-title":"FDA approves long-acting RSV antibody","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.721328","article-title":"Review: insights on current FDA-approved monoclonal antibodies against ebola virus infection","volume":"12","author":"Tshiani Mbaya","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179763","article-title":"Evolution of anti-SARS-CoV-2 therapeutic antibodies","volume":"23","author":"Almagro","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105867","article-title":"Progress in novel delivery technologies to improve efficacy of therapeutic antibodies","volume":"225","author":"Sun","year":"2024","journal-title":"Antiviral Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2024.04.039","article-title":"Emerging advances in delivery systems for mRNA cancer vaccines","volume":"370","author":"Jiang","year":"2024","journal-title":"J Control Release"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13122014","article-title":"Current and emerging strategies for enhancing antibody delivery to the brain","volume":"13","author":"Bajracharya","year":"2021","journal-title":"Pharmaceutics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105834","article-title":"Viral and non-viral vectors in gene therapy: current state and clinical perspectives","volume":"118","author":"Geng","year":"2025","journal-title":"eBioMedicine"},{"key":"B17","first-page":"14","article-title":"A brief synopsis of monoclonal antibody for the treatment of various groups of diseases","volume":"10","author":"Puthenpurail","year":"2021","journal-title":"World J Pharm Pharm Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study","volume":"393","author":"Gaudinski","year":"2019","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1990.tb08085.x","article-title":"Expression and targeting of intracellular antibodies in mammalian cells","volume":"9","author":"Biocca","year":"1990","journal-title":"EMBO J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(88)90263-2","article-title":"Cellular uptake of the tat protein from human immunodeficiency virus","volume":"55","author":"Frankel","year":"1988","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1632705","article-title":"Another power of antibody-drug conjugates: immunomodulatory effect and clinical applications","volume":"16","author":"Shi","year":"2025","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab govitecan (IMMU-132), an Anti-Trop-2\/SN-38 antibody-drug conjugate: Characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug Chem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01207-9","article-title":"Fifty years of monoclonals: the past, present and future of antibody therapeutics","volume":"25","author":"Chan","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1999.00845.x","article-title":"Normal human immunoglobulin G4 is bispecific: It has two different antigen-combining sites","volume":"97","author":"Schuurman","year":"1999","journal-title":"Immunology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1021\/ja203638y","article-title":"Mechanism of immunoglobulin G4 Fab-arm exchange","volume":"133","author":"Rispens","year":"2011","journal-title":"J Am Chem Soc"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(61)90296-X","article-title":"Recombination of a mixture of univalent antibody fragments of different specificity","volume":"93","author":"Nisonoff","year":"1961","journal-title":"Arch Biochem Biophys"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.2.11221","article-title":"Catumaxomab: Clinical development and future directions","volume":"2","author":"Linke","year":"2010","journal-title":"MAbs"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2020.03.034","article-title":"Treatment options for COVID-19: The reality and challenges","volume":"53","author":"Jean","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV)","volume":"30","author":"Wang","year":"2020","journal-title":"vitro. Cell Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5152\/eurjrheum.2022.22028","article-title":"Severe infections in patients treated with tocilizumab for systemic diseases other than rheumatoid arthritis: A retrospective multicenter observational study","volume":"10","author":"Broca","year":"2023","journal-title":"Eur J Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Abani","year":"2021","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.109902","article-title":"A tetravalent bispecific antibody outperforms the combination of its parental antibodies and neutralizes diverse SARS-CoV-2 variants","volume":"260","author":"Chiyyeadu","year":"2024","journal-title":"Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e04690","DOI":"10.1002\/advs.202504690","article-title":"Engineered dual-function antibody-like proteins to combat SARS-CoV-2-induced immune dysregulation and inflammation","volume":"12","author":"Wang","year":"2025","journal-title":"Adv Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105924","article-title":"A fusion protein approach to integrate antiviral and anti-inflammatory activities for developing new therapeutics against influenza A virus infection","volume":"228","author":"Zhai","year":"2024","journal-title":"Antiviral Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2014.09.001","article-title":"The history of monoclonal antibody development - Progress, remaining challenges and future innovations","volume":"3","author":"Liu","year":"2014","journal-title":"Ann Med Surg"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.46134","article-title":"Tailored tetravalent antibodies potently and specifically activate wnt\/frizzled pathways in cells, organoids and mice","volume":"8","author":"Tao","year":"2019","journal-title":"Elife"},{"key":"B37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(24)00447-2","article-title":"Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicentre, placebo-controlled, phase 2b trial","volume":"24","author":"Weidner","year":"2025","journal-title":"Lancet Neurol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01290","article-title":"Mechanisms of cancer resistance to immunotherapy","volume":"10","author":"Bai","year":"2020","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1524945","article-title":"Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis","volume":"16","author":"Lallas","year":"2025","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/JDV.20672","article-title":"Survival after cessation of immunotherapies in melanoma: A systematic review and meta-analysis","volume":"39","author":"Mayer","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e2381","DOI":"10.1002\/RMV.2381","article-title":"Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission","volume":"32","author":"Shrestha","year":"2022","journal-title":"Rev Med Virol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41564-025-02030-7","article-title":"Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants","volume":"10","author":"Jian","year":"2025","journal-title":"Nat Microbiol 2025"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1038\/s41467-024-48139-x","article-title":"Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding","volume":"15","author":"Bai","year":"2024","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1093\/INFDIS\/JIY696","article-title":"Immunodominance and antigenic variation of influenza virus hemagglutinin: implications for design of universal vaccine immunogens","volume":"219","author":"Zost","year":"2019","journal-title":"J Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.10.6721-6726.2005","article-title":"Working mechanism of immunoglobulin A1 (IgA1) protease: Cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 protease","volume":"73","author":"Vidarsson","year":"2005","journal-title":"Infect Immun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.12.5826-5832.1998","article-title":"Evaluation of immunoglobulin A1 (IgA1) protease and igA1 protease-inhibitory activity in human female genital infection with neisseria gonorrhoeae","volume":"66","author":"Hedges","year":"1998","journal-title":"Infect Immun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/J.PEP.2012.04.023","article-title":"Human cells: New platform for recombinant therapeutic protein production","volume":"84","author":"Swiech","year":"2012","journal-title":"Protein Expr Purif"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/FBIOE.2019.00420","article-title":"Recent developments in bioprocessing of recombinant proteins: expression hosts and process development","volume":"7","author":"Tripathi","year":"2019","journal-title":"Front Bioeng Biotechnol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/FBIOE.2021.630551","article-title":"Challenges associated with the formation of recombinant protein inclusion bodies in escherichia coli and strategies to address them for industrial applications","volume":"9","author":"Bhatwa","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444906029799","article-title":"A time- and cost-efficient system for high-level protein production in mammalian cells","volume":"62","author":"Aricescu","year":"2006","journal-title":"urn:issn:0907-4449"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2014.00172","article-title":"Recombinant protein expression in Escherichia coli: Advances and challenges","volume":"5","author":"Rosano","year":"2014","journal-title":"Front Microbiol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"695","DOI":"10.4161\/mabs.2.6.13603","article-title":"Metrics for antibody therapeutics development","volume":"2","author":"Reichert","year":"2010","journal-title":"MAbs"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0512-5","article-title":"Developing therapeutic monoclonal antibodies at pandemic pace","volume":"38","author":"Kelley","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12597","article-title":"Pharmacokinetic and pharmacodynamic considerations in the design of therapeutic antibodies","volume":"12","author":"Leipold","year":"2019","journal-title":"Clin Transl Sci"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-46321-9","article-title":"Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria","volume":"15","author":"Foss","year":"2024","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11061610","article-title":"Mechanisms of action and limitations of monoclonal antibodies and single chain fragment variable (scFv) in the treatment of cancer","volume":"11","author":"Rodr\u00edguez-Nava","year":"2023","journal-title":"Biomedicines"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1368173","article-title":"Subcutaneous administration of monoclonal antibodies in oncology","volume":"74","author":"Jackisch","year":"2014","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"B58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/S13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/PSP4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHARMTHERA.2021.108022","article-title":"Therapeutic antibodies \u2013 natural and pathological barriers and strategies to overcome them","volume":"233","author":"Al Ojaimi","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"4011","author":"Rohner","year":"2022","journal-title":"Nat Biotechnol 2022"},{"key":"B62","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1186\/S40001-025-03060-X","article-title":"Research progress of mRNA vaccines for infectious diseases","volume":"30","author":"Zhang","year":"2025","journal-title":"Eur J Med Res"},{"key":"B63","doi-asserted-by":"crossref","DOI":"10.34133\/research.0370","article-title":"Unlocking the therapeutic applicability of LNP-mRNA: chemistry, formulation, and clinical strategies","volume":"7","author":"Huang","year":"2024","journal-title":"Research"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.809118","article-title":"Gene therapy advances: A meta-analysis of AAV usage in clinical settings","volume":"8","author":"Au","year":"2022","journal-title":"Front Media S.A"},{"key":"B65","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/S41434-023-00390-5","article-title":"Successes and challenges in clinical gene therapy","volume":"30","author":"Kohn","year":"2023","journal-title":"Gene Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/J.YMTHE.2025.04.045","article-title":"Current clinical applications of AAV-mediated gene therapy","volume":"33","author":"Byrne","year":"2025","journal-title":"Mol Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Springer Nature"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0106-0","article-title":"The estimated annual financial impact of gene therapy in the United States","volume":"30","author":"Wong","year":"2023","journal-title":"Gene Ther"},{"key":"B69","unstructured":"Clinical use of lentiviral vectors\n          \n          \n            \n              Milone\n              MC\n            \n            \n              O\u2019Doherty\n              U\n            \n          \n          10.1038\/s41375-018-0106-0\n          29654266\n          Leukemia\n          Nature Publishing Group\n          Leukemia\n          \n          2018"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nature15818","article-title":"Gene therapy returns to centre stage","volume":"526","author":"Naldini","year":"2015","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00702","article-title":"Prolonged persistence of chimeric antigen receptor (CAR) T cell in adoptive cancer immunotherapy: challenges and ways forward","volume":"11","author":"Jafarzadeh","year":"2020","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.878209","article-title":"CAR-T cell performance: how to improve their persistence","volume":"13","author":"L\u00f3pez-Cantillo","year":"2022","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"206","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol 2023"},{"key":"B74","volume-title":"The Kidney Project","year":""},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2024.06.014","article-title":"Viral nephropathies: core curriculum 2024","volume":"84","author":"Yau","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30240-9","article-title":"Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: A multinational cross-sectional study","volume":"387","author":"Mehta","year":"2016","journal-title":"Lancet"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2023.151466","article-title":"Infections and acute kidney injury: A global perspective","volume":"43","author":"Batte","year":"2023","journal-title":"Semin Nephrol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-470X(10)80027-8","article-title":"OKT3 in organ transplantation","volume":"5","author":"Kreis","year":"1991","journal-title":"Transplant Rev"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1159\/000184433","article-title":"Therapeutic use of OKT3 monoclonal antibody for acute renal allograft rejection","volume":"46","author":"Norman","year":"1987","journal-title":"Nephron"},{"key":"B80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"94","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov 2010"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/J.1432-2277.1992.TB01753.X","article-title":"Monoclonal antibodies in renal transplantation: a review","volume":"5","author":"Parlevliet","year":"1992","journal-title":"Transpl Int"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1126\/SCIENCE.ABN7760","article-title":"SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein\u2013ACE2 complex","volume":"375","author":"Mannar","year":"2022","journal-title":"Science"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2024.1433452","article-title":"Mucosal immunity in COVID-19: a comprehensive review","volume":"15","author":"Alqahtani","year":"2024","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01065-y","article-title":"How much does it cost to research and develop a new drug? A systematic review and assessment","volume":"39","author":"Schlander","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2297450","article-title":"Antibodies to watch in 2024","volume":"16","author":"Crescioli","year":"2024","journal-title":"MAbs"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle","volume":"247","author":"Wolff","year":"1990","journal-title":"vivo. Sci (80-)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"372","author":"Stamatatos","year":"2021","journal-title":"Science (80-)"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt1330","article-title":"The contribution of pseudouridine to stabilities and structure of RNAs","volume":"42","author":"Kierzek","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol Ther"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.3c00185","article-title":"Looking back, moving forward: lipid nanoparticles as a promising frontier in gene delivery","volume":"6","author":"Pozzi","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add4623","article-title":"Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates","volume":"9","author":"Herrera-Barrera","year":"2023","journal-title":"Sci Adv"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.4c01854","article-title":"Lung-specific mRNA delivery enabled by sulfonium lipid nanoparticles","volume":"24","author":"Popoola","year":"2024","journal-title":"Nano Lett"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307801120","article-title":"Cationic cholesterol-dependent LNP delivery to lung stem cells, the liver, and heart","volume":"121","author":"Radmand","year":"2024","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116271119","article-title":"Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis","volume":"119","author":"Qiu","year":"2022","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101253","article-title":"An mRNA-based platform for the delivery of pathogen-specific IgA into mucosal secretions","volume":"4","author":"Deal","year":"2023","journal-title":"Cell Rep Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/bjbs.2025.14557","article-title":"A Systematic Review of Clinical Trials Using mRNA Vaccines for Infectious Diseases other than COVID-19","volume":"82","author":"Sofroniou","year":"2025","journal-title":"Br J BioMed Sci"},{"key":"B98","volume-title":"Cellular & Gene Therapy Guidances","year":""},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS13101675","article-title":"Lipid nanoparticles for organ-specific mRNA therapeutic delivery","volume":"13","author":"\u017bak","year":"2021","journal-title":"Pharmaceutics"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1021\/acsnanoscienceau.2c00062","article-title":"Composition of lipid nanoparticles for targeted delivery: application to mRNA therapeutics","volume":"15","author":"Vasileva","year":"2024","journal-title":"Front Pharmacol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1021\/acsnanoscienceau.2c00062","article-title":"Recent advances in site-specific lipid nanoparticles for mRNA delivery","volume":"3","author":"Xu","year":"2023","journal-title":"Am Chem Society"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e2109256118","DOI":"10.1073\/PNAS.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1126\/SCIENCE.ABM0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science (80-)"},{"key":"B104","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat Commun"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121707","article-title":"Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting the injured intestinal mucosa: A novel therapeutic solution to treat ulcerative colitis","volume":"288","author":"Sung","year":"2022","journal-title":"Biomaterials"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1021\/JACS.2C02706","article-title":"Rational design of bisphosphonate lipid-like materials for mRNA delivery to the bone microenvironment","volume":"144","author":"Xue","year":"2022","journal-title":"J Am Chem Soc"},{"key":"B107","doi-asserted-by":"publisher","first-page":"7264","DOI":"10.1038\/s41467-021-27434-x","article-title":"Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy","volume":"12","author":"Li","year":"2021","journal-title":"Nat Commun"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.4.10.2072-2081.1984","article-title":"A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase","volume":"4","author":"Tratschin","year":"1984","journal-title":"Mol Cell Biol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.20.6466","article-title":"Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells","volume":"81","author":"Hermonat","year":"1984","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B110","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1089\/HUM.2024.114","article-title":"Adeno-associated virus vectors\u2014a target of cellular and humoral immunity\u2014are expanding their reach toward hematopoietic stem cell modification and immunotherapies","volume":"35","author":"Araujo","year":"2024","journal-title":"Human Gene Therapy"},{"key":"B111","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/HUM.2019.220","article-title":"Can adeno-associated viral vectors deliver effectively large genes","volume":"31","author":"Tornabene","year":"2020","journal-title":"Human Gene Therapy"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymthe.2025.09.007","article-title":"AAV-mediated delivery of a broadly neutralizing anti-flavivirus antibody protects against dengue and Zika viruses in a mouse model","volume":"33","author":"Ko","year":"2025","journal-title":"Mol Ther"},{"key":"B114","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature14264","article-title":"AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges","volume":"519","author":"Gardner","year":"2015","journal-title":"Nature"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3390\/VACCINES6030035","article-title":"Neutralizing anti-hemagglutinin monoclonal antibodies induced by gene-based transfer have prophylactic and therapeutic effects on influenza virus infection","volume":"6","author":"Yamazaki","year":"2018","journal-title":"Vaccines"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/J.OMTM.2019.01.008","article-title":"Capsid modifications for targeting and improving the efficacy of AAV vectors","volume":"12","author":"B\u00fcning","year":"2019","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/J.YMTHE.2025.03.064","article-title":"AAV vector development, back to the future","volume":"33","author":"Suarez-Amaran","year":"2025","journal-title":"Mol Ther"},{"key":"B118","doi-asserted-by":"publisher","first-page":"187ra72","DOI":"10.1126\/scitranslmed.3006299","article-title":"Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza","volume":"5","author":"Limberis","year":"2013","journal-title":"Sci Transl Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/v16030442","article-title":"Natural adeno-associated virus serotypes and engineered adeno-associated virus capsid variants: tropism differences and mechanistic insights","volume":"16","author":"Lopez-Gordo","year":"2024","journal-title":"Viruses"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.852003","article-title":"Alpha-synuclein targeting therapeutics for parkinson\u2019s disease and related synucleinopathies","volume":"13","author":"Menon","year":"2022","journal-title":"Front Neurol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-240207","article-title":"The AAV-\u03b1-synuclein model of parkinson\u2019s disease: an update","volume":"14","author":"Bj\u00f6rklund","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/FNEUR.2022.870799","article-title":"AAV vector-mediated antibody delivery (A-MAD) in the central nervous system","volume":"13","author":"Marino","year":"2022","journal-title":"Front Neurol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/J.BRAINRES.2025.150047","article-title":"Next-generation neurotherapeutics: mechanistic insights on monoclonal antibodies in Alzheimer\u2019s disease","volume":"1870","author":"Sharma","year":"2026","journal-title":"Brain Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2025.115138","article-title":"Virus-mediated delivery of single-chain antibody targeting TDP-43 protects against neuropathology, cognitive impairment and motor deficit caused by chronic cerebral hypoperfusion","volume":"385","author":"Chami","year":"2025","journal-title":"Exp Neurol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1089\/JOP.2021.0001","article-title":"Comprehensive preclinical assessment of ADVM-022, an intravitreal anti-VEGF gene therapy for the treatment of neovascular AMD and diabetic macular edema","volume":"37","author":"Gelfman","year":"2021","journal-title":"J Ocul Pharmacol Ther"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"B128","article-title":"Phase 1 study of intravitreal gene therapy ADVM-022 for neovascular AMD (OPTIC trial)","volume":"61","author":"Khanani","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of transgene expression after rAAV gene therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol Ther"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1126\/SCIIMMUNOL.ADQ4973","article-title":"Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy","volume":"10","author":"Klenchin","year":"2025","journal-title":"Sci Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.04.007","article-title":"The impact of lentiviral vector genome size and producer cell genomic to gag-pol mRNA ratios on packaging efficiency and titre","volume":"21","author":"Sweeney","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-41644-x","article-title":"Quantitation and integrity evaluation of RNA genome in lentiviral vectors by direct reverse transcription-droplet digital PCR (direct RT-ddPCR)","volume":"13","author":"He","year":"2023","journal-title":"Sci Rep"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.08.005","article-title":"Rapid in-process monitoring of lentiviral vector particles by high-performance liquid chromatography","volume":"18","author":"Transfiguracion","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.2174\/1566523054546224","article-title":"Altering the tropism of lentiviral vectors through pseudotyping","volume":"5","author":"Cronin","year":"2005","journal-title":"Curr Gene Ther"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3390\/V13081526","article-title":"Designing lentiviral vectors for gene therapy of genetic diseases","volume":"13","author":"Poletti","year":"2021","journal-title":"Viruses"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"Journal of Virology"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.5","article-title":"Physiological promoters reduce the genotoxic risk of integrating gene vectors","volume":"16","author":"Zychlinski","year":"2008","journal-title":"Mol Ther"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37630","article-title":"The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy","volume":"119","author":"Montini","year":"2009","journal-title":"J Clin Invest"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.06.017","article-title":"Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning","volume":"29","author":"Schwarzer","year":"2021","journal-title":"Mol Ther"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.08.017","article-title":"Development of an in vitro genotoxicity assay to detect retroviral vector-induced lymphoid insertional mutants","volume":"30","author":"Bastone","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/S0958-1669(98)80029-3","article-title":"Lentiviruses as gene transfer agents for delivery to non-dividing cells","volume":"9","author":"Naldini","year":"1998","journal-title":"Curr Opin Biotechnol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2021.12.033","article-title":"Improved alpharetrovirus-based Gag.MS2 particles for efficient and transient delivery of CRISPR-Cas9 into target cells","volume":"27","author":"Baron","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-260-5_10","article-title":"Retrovirus-based mRNA transfer for transient cell manipulation","volume":"969","author":"Galla","year":"2013","journal-title":"Methods Mol Biol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2008.189","article-title":"Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells","volume":"20","author":"Gennari","year":"2009","journal-title":"Hum Gene Ther"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2005.16.223","article-title":"Cell type-specific targeting with sindbis pseudotyped lentiviral vectors displaying anti-CCR5 single-chain antibodies","volume":"16","author":"Aires Da Silva","year":"2005","journal-title":"Hum Gene Ther"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.206","article-title":"Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells","volume":"19","author":"Goyvaerts","year":"2012","journal-title":"Gene Ther"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1128\/MBIO.02990-19","article-title":"Efficient and highly specific gene transfer using mutated lentiviral vectors redirected with bispecific antibodies","volume":"11","author":"Parker","year":"2020","journal-title":"MBio"},{"key":"B149","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/J.OMTM.2018.10.006","article-title":"Surface-engineered lentiviral vectors for selective gene transfer into subtypes of lymphocytes","volume":"12","author":"Frank","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOMATERIALS.2014.01.051","article-title":"Systematic improvement of lentivirus transduction protocols by antibody fragments fused to VSV-G as envelope glycoprotein","volume":"35","author":"H\u00f6fig","year":"2014","journal-title":"Biomaterials"},{"key":"B151","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.omtm.2019.11.004","article-title":"Dosing and re-administration of lentiviral vector for in vivo gene therapy in rhesus monkeys and ADA-deficient mice","volume":"16","author":"Carbonaro-Sarracino","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B152","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.omtm.2017.03.009","article-title":"Toward personalized gene therapy: characterizing the host genetic control of lentiviral-vector-mediated hepatic gene delivery","volume":"5","author":"Suwanmanee","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B153","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1038\/mtna.2013.49","article-title":"Integration-specific in vitro evaluation of lentivirally transduced rhesus CD34+ cells correlates with in vivo vector copy number","volume":"2","author":"Uchida","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.161598","article-title":"Directly injected lentiviral vector-based T cell vaccine protects mice against acute and chronic viral infection","volume":"7","author":"Tada","year":"2022","journal-title":"JCI Insight"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/tid.13189","article-title":"The impact of recurrent cytomegalovirus infection on long-term survival in solid organ transplant recipients","volume":"21","author":"Gardiner","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02197-9","article-title":"Viral oncogenesis in cancer: from mechanisms to therapeutics","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B157","article-title":"Common questions about infectious mononucleosis","volume":"91","author":"Womack","year":"2015","journal-title":"Am Fam Physician"},{"key":"B158","volume-title":"Epstein-Barr virus: From harmless to severe consequences","year":""},{"key":"B159","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00432-021-03824-y","article-title":"Estimating the global\u00a0burden of Epstein\u2013Barr virus-related cancers","volume":"148","author":"Wong","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.0604993103","article-title":"Targeting lentiviral vectors to specific cell types in vivo","volume":"103","author":"Yang","year":"2006","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B162","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/J.BIOMATERIALS.2013.10.026","article-title":"Genetic engineering of cell lines using lentiviral vectors to achieve antibody secretion following encapsulated implantation","volume":"35","author":"Lathuili\u00e8re","year":"2014","journal-title":"Biomaterials"},{"key":"B163","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41587-025-02616-w","article-title":"First inhaled lentiviral gene therapy enters cystic fibrosis trial","volume":"43","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B164","volume-title":"A long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair\u2122-ON)","year":""},{"key":"B165","volume-title":"Safety and Efficacy of T Cell Genetic Immunotherapy for HIV","year":""},{"key":"B166","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/S41467-017-01901-W","article-title":"Plasma cell survival in the absence of B cell memory","volume":"8","author":"Hammarlund","year":"2017","journal-title":"Nat Commun"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRIM.2022.101726","article-title":"Bone marrow derived long-lived plasma cell phenotypes are heterogeneous and can change in culture","volume":"75","author":"Mujtahedi","year":"2022","journal-title":"Transpl Immunol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01340-w","article-title":"The secret to longevity, plasma cell style","volume":"23","author":"Tellier","year":"2022","journal-title":"Nat Immunol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00965","article-title":"Survival of long-lived plasma cells (LLPC): Piecing together the puzzle","volume":"10","author":"Lightman","year":"2019","journal-title":"Front Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7624","article-title":"Edward Donnall Thomas","volume":"345","author":"Kermode-Scott","year":"2012","journal-title":"Bmj"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-024-00094-4","article-title":"The changing landscape of cancer cell therapies: clinical trials and real-world data","volume":"23","author":"Saez-Iba\u00f1ez","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B172","volume-title":"Immuno-Oncology Landscape","year":""},{"key":"B173","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nrd.2017.196","article-title":"FDA approves first CAR T therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016101","article-title":"Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRP\u03b1 checkpoint blocker","volume":"141","author":"Dacek","year":"2023","journal-title":"Blood"},{"key":"B175","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.omtm.2020.08.008","article-title":"Safety and efficacy of an immune cell-specific chimeric promoter in regulating anti-PD-1 antibody expression in CAR T cells","volume":"19","author":"Fang","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1368732","article-title":"Prospects and challenges of CAR-T cell therapy combined with ICIs","volume":"14","author":"Lv","year":"2024","journal-title":"Front Oncol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03187-1","article-title":"Engineering of \u03b1-PD-1 antibody-expressing long-lived plasma cells by CRISPR\/Cas9-mediated targeted gene integration","volume":"11","author":"Luo","year":"2020","journal-title":"Cell Death & Disease"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1021\/ACSSYNBIO.0C00097","article-title":"Comprehensive analysis of genomic safe harbors as target sites for stable expression of the heterologous gene in HEK293 cells","volume":"9","author":"Shin","year":"2020","journal-title":"ACS Synth Biol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/J.CRMETH.2021.100154","article-title":"Discovery and validation of human genomic safe harbor sites for gene and cell therapies","volume":"2","author":"Aznauryan","year":"2022","journal-title":"Cell Rep Methods"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/J.ISCI.2023.108287","article-title":"CRISPR-Cas12a-integrated transgenes in genomic safe harbors retain high expression in human hematopoietic iPSC-derived lineages and primary cells","volume":"26","author":"Vlassis","year":"2023","journal-title":"iScience"},{"key":"B182","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/B978-0-12-410396-2.00007-4","article-title":"Cell therapy landscape: autologous and allogeneic approaches","author":"Malik","year":"2015","journal-title":"Transl Regener Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.38","article-title":"Gene insertion into genomic safe harbors for human gene therapy","volume":"24","author":"Papapetrou","year":"2016","journal-title":"Mol Ther"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-33787-8","article-title":"Ex vivo engineered human plasma cells exhibit robust protein secretion and long-term engraftment","volume":"13","author":"Cheng","year":"2022","journal-title":"vivo. Nat Commun"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01328-9","article-title":"In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice","volume":"40","author":"Nahmad","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19649-1","article-title":"Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion","volume":"11","author":"Nahmad","year":"2020","journal-title":"Nat Commun"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755639","article-title":"Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-cell Malignancies","volume":"12","author":"Guercio","year":"2021","journal-title":"Front Immunol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-023-00404-2","article-title":"RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells","volume":"30","author":"Bouquet","year":"2023","journal-title":"Gene Ther"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/J.STEM.2025.03.004","article-title":"Progress and challenges in developing allogeneic cell therapies","volume":"32","author":"Deuse","year":"2025","journal-title":"Cell Stem Cell"},{"key":"B190","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/INTIMM\/DXAD051","article-title":"Trends in cell medicine: from autologous cells to allogeneic universal-use cells for adoptive T-cell therapies","volume":"36","author":"Kawamoto","year":"2024","journal-title":"Int Immunol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1200180","article-title":"Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety\/efficacy outcomes, cell product manufacturing and clinical delivery","volume":"14","author":"Couto","year":"2023","journal-title":"Front Immunol"},{"key":"B192","volume-title":"BeCoMe-9: A clinical study of BE-101 for the Treatment of Adults\u00a0With Moderately Severe or Severe Hemophilia B","year":""},{"key":"B193","volume-title":"ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I","year":""},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw036","article-title":"AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment of active ulcerative colitis: Results of a first-in-human trial","volume":"10","author":"Harris","year":"2016","journal-title":"J Crohn\u2019s Colitis"},{"key":"B195","volume-title":"To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen","year":""},{"key":"B196","volume-title":"A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients","year":""},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01880-07","article-title":"Cellular restriction of retrovirus\u00a0particle-mediated mRNA transfer","volume":"82","author":"Galla","year":"2008","journal-title":"J Virol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1089\/HUM.2011.011","article-title":"Pseudotype-independent nonspecific uptake of gammaretroviral and lentiviral particles in human cells","volume":"23","author":"Voelkel","year":"2012","journal-title":"Hum Gene Ther"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2004.09.023","article-title":"Retroviral pseudotransduction for targeted cell manipulation","volume":"16","author":"Galla","year":"2004","journal-title":"Mol Cell"},{"key":"B200","volume-title":"Safety and Preliminary Efficacy Trial of BNT142 in Patients\u00a0With CLDN6-positive Solid Tumors","year":""},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl2720","article-title":"Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6","volume":"16","author":"Stadler","year":"2024","journal-title":"Sci Transl Med"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-55843-9","article-title":"Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers","volume":"16","author":"Maine","year":"2025","journal-title":"Nat Commun"},{"key":"B203","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1002\/mco2.645","article-title":"Current developments of gene therapy in human diseases","volume":"5","author":"Liu","year":"2024","journal-title":"MedComm"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2016-16.2016","article-title":"Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice","volume":"36","author":"Liu","year":"2016","journal-title":"J Neurosci"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"B206","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v17060802","article-title":"Progress in pseudotyping lentiviral vectors towards cell-specific gene delivery","volume":"17","author":"Arduini","year":"2025","journal-title":"In vivo. Viruses"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1489827","article-title":"Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors","volume":"15","author":"Khan","year":"2024","journal-title":"Front Immunol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1649045","article-title":"Editorial: Expanding CAR-T cell therapy \u2014 breakthroughs from cancer to autoimmune diseases","volume":"16","author":"Nunez-Cruz","year":"2025","journal-title":"Front Immunol"},{"key":"B209","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/S12929-025-01190-2","article-title":"Technological advancements in antibody-based therapeutics for treatment of diseases","volume":"32","author":"Lu","year":"2025","journal-title":"J BioMed Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1714390\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:53:11Z","timestamp":1767768791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1714390\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":209,"alternative-id":["10.3389\/fimmu.2025.1714390"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1714390","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1714390"}}